3 Minute Read
Keep up-to-date on Branded Prescription Drug Fees with this summary of critical insights from Nick Lynch, Partner at IntegriChain, covering key deadlines and factors.
4 Minute Read
In this blog, we recap the key insights shared by Nick Lynch, Partner at IntegriChain, and Suriya Janarthanan, Associate Director at Novartis, on how manufacturers can navigate FMV and...
2 Minute Read
In today’s rapidly evolving pharmaceutical landscape, creating an effective commercial data strategy is critical for achieving success.
4 Minute Read
As the industry approaches full compliance with DSCSA requirements, new challenges emerge, particularly in managing data discrepancies, addressing inventory exceptions, and navigating gross-to-net impacts.
3 Minute Read
Read the latest on the CMS September Final Rule Overview & a Controversial 340B Rebate Policy
3 Minute Read
Katie Herrick and Dan Landis, consultants from Blue Fin Group, discuss how pharmaceutical companies are adapting to the changing healthcare environment by focusing on improving patient access and affordability.
4 Minute Read
Nick Lynch, Partner of Federal Compliance Solutions (FCS) discusses insights into recent developments in pharmaceutical pricing, focusing on government programs like 340B, Medicaid Drug Rebate Program (MDRP), Medicare Part...
3 Minute Read
Learn about the IRA's changes to Part D benefits have created uncertainty for both manufacturers and payers.
3 Minute Read
Discover the latest on the Pharmacy Reimbursements for CVS, FSS/IFF Reporting Alert, and the 340B Drug Discount Program.